Results 61 to 70 of about 231,116 (154)

Neoadjuvant combination immunotherapy for colorectal cancer: clinical and molecular predictors of pathological complete response and safety assessment

BMC Gastroenterology
Purpose To identify the clinical and molecular factors that effectively predict pathological complete response (pCR) and assess the safety of patients receiving neoadjuvant combination immunotherapy. Methods This retrospective study evaluated 81 patients
Yuegang Li, Meng Zhuang, Shiwen Mei, Jianqiang Tang   +3 more
doaj   +1 more source

Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis

Heliyon
Background: There is no standard consensus on the optimal number of cycles of neoadjuvant immunotherapy prior to surgery for patients with locoregionally advanced non-small cell lung cancer (NSCLC).
Linlin Ye, Yao Liu, Xuan Xiang, Zihao Wang, Wenbei Peng, Xiaoshan Wei, Siyu Zhang, Qianqian Xue, Qiong Zhou   +8 more
doaj   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
Jens Huober, Reinisch, Mattea, Sibylle Loibl, Silvia Darb-Esfahani, Michael Untch, Hans Tesch, Martin-Leo Hansmann, Jan C Brase, Knut Engels, Judith Prinzler, Keyur Mehta, Minckwitz, Gunter von, Brase, Jan C., Kronenwett, Ralf, Hansmann, Martin-Leo, Huober, Jens, Engels, Knut, Solbach, Christine, Tesch, Hans, Carsten Denkert, Denkert, Carsten, Gunter von Minckwitz, Bruno V Sinn, Loibl, Sibylle, Mattea Reinisch, Peter A Fasching, Sinn, Bruno V., Ralf Kronenwett, Christine Solbach, Prinzler, Judith, Mehta, Keyur, Fasching, Peter Andreas, Untch, Michael, Denkert, Carsten Michael, Darb-Esfahani, Silvia   +34 more
core   +2 more sources

Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis

Systematic Reviews
Introduction Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer-related deaths globally. Despite surgery being the main treatment for resectable NSCLC, many patients experience postoperative recurrence. Neoadjuvant
Qiong Zhang, Jia Duan, Yuanmei Zhang, Lei Yang, Duo Li   +4 more
doaj   +1 more source

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives

Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with a modest impact on overall survival. The current treatment options for early-stage resectable NSCLC include neoadjuvant, adjuvant, and perioperative
Jeffrey M. Clarke, Laura Alder, Jordyn P. Higgins, Diamone Gathers, Cameron Oswalt, Eziafa I. Oduah, Kevin Chen   +6 more
core   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review

Frontiers in Immunology
BackgroundNeoadjuvant therapy for resectable gastric cancer/gastroesophageal junction tumors is progressing slowly. Although immunotherapy for advanced gastric cancer/gastroesophageal junction tumors has made great progress, the efficacy and safety of ...
Jincheng Wang, Ti Tong, Guangxin Zhang, Chengyan Jin, Haiping Guo, Xueying Liu, Zhengxiao Zhang, Jindong Li, Yinghao Zhao   +8 more
doaj   +1 more source

Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy for Stage III NSCLC: A Systematic Review and Meta-Analysis

Background. To comprehensively assess surgical safety, we conducted a meta-analysis on neoadjuvant chemo-immunotherapy for NSCLC. Methods. This systematic review and meta-analysis followed PRISMA guidelines (PROSPERO: CRD42023470682). A literature search
Lorenzo Spaggiari, Antonio Mazzella, Giuseppe Nicolosi, Alessia De Fabiani, Claudia Bardoni, Luca Bertolaccini, Cristina Diotti, Monica Casiraghi, Matteo Chiari   +8 more
core   +1 more source

Immunotherapy in Early and Locally Advanced Stage Non-small Cell Lung Cancer

Acta Haematologica Oncologica Turcica
Non-small cell lung cancer (NSCLC) is important for public health as it is one of the major causes of cancer-related deaths worldwide. The use of immunotherapy in NSCLC is becoming increasingly widespread. Immunotherapies are currently used in metastatic
Abdülkadir Koçanoğlu, Yakup Düzköprü, Serdar Karakaya   +2 more
doaj   +1 more source

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis [PDF]

Cancers (Basel)
Background: Evidence suggests dMMR/MSI-H gastric cancer patients respond better to immune checkpoint inhibitors (ICIs) than to chemotherapy, but recent trials have not consistently shown this benefit in subgroup analyses.
Pang H, Chen Y, Zhao Z, Chen Z, Yan M, Yi B, Chen X, Sun H.   +7 more
europepmc   +2 more sources